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INTRODUCTION
Gonadotrophin-releasing hormone (GnRH) analogues
have been widely used for pituitary suppression in women
undergoing controlled ovarian hyperstimulation (COH) for
in vitro fertilization and embryo transfer (IVF-ET) cycle. The
benefits of GnRH analogues are principally the reduction of
serum luteinizing hormone (LH) concentration and the pre-
vention of premature LH surge (1, 2). As a consequence of
low LH concentration and prevention of LH surge, the inci-
dence of cycle cancellation would be decreased and the con-
venience of both patient and physician would be improved
(3, 4). Local ovarian androgen concentration is also reduced
by the low level of LH, and this increased estrogen/androgen
ratio improves oocyte development (5). Moreover, GnRH ana-
logues contribute partly to improving endometrial receptivi-
ty and widening implantation window (6, 7). Overall, these
benefits cause augmentation of mature oocytes and pregnan-
cy rate in IVF-ET cycles (8-10).
Diverse GnRH analogues have been developed with differ-
ent chemical structures, biological activity, half-life, and the
routes of administration. Among the various COH protocols
of combining GnRH analogues and gonadotrophins, the
long protocol has been known as a more efficient method
because of its adequate pituitary suppression and better suc-
cess rate in comparison with the short protocol (11, 12). The
factors taken into consideration when choosing the appropri-
ate GnRH analogue for COH are: 1) the adequacy of pitu-
itary suppression, 2) retrieval of high number of good oocytes,
3) length and cost of COH, as well as 4) outcome of pregnan-
cy. In addition, the convenience of COH protocol is another
important point to consider so as not to interfere with the
patient’s well-being. For example, multiple daily injections
of the drug not only can cause frequent pain but also result
in more time spent visiting hospital during COH.
Several studies were performed to compare the efficacy
between long-acting GnRH agonist (GnRHa) and short-act-
ing GnRHa (13-16). No significant differences in gonado-
trophin doses, the duration of stimulation, the number of
retrieved oocytes, fertilization rates as well as pregnancy rates
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Comparison of Clinical Efficacy between a Single Administration of
Long-Acting Gonadotrophin-Releasing Hormone Agonist (GnRHa) and
Daily Administrations of Short-Acting GnRHa in In Vitro Fertilization-
Embryo Transfer Cycles
This study was aimed to evaluate the efficacy of a single administration of long-act-
ing gonadotrophin-releasing hormone agonist (GnRHa) as compared with daily
administrations of short-acting GnRHa in controlled ovarian hyperstimulation (COH)
for in vitro fertilization and embryo transfer (IVF-ET) cycles. The mean dosage of
recombinant follicle-stimulating hormone (rFSH) required for COH (2,354.5± ±244.2
vs. 2,012.5± ±626.1 IU) and the rFSH dosage per retrieved oocyte (336.7± ±230.4
vs. 292.1± ±540.4 IU) were significantly higher in the long-acting GnRHa group (N=
22) than those in the short-acting GnRHa group (N=28) (p<0.05). However, the mean
number of visit to the hospital that was required before ovum pick-up (3.3± ±0.5 vs.
22.2± ±2.0) and the frequency of injecting GnRHa and rFSH (12.8± ±1.2 vs. 33.5± ±
3.5) were significantly decreased in the long-acting GnRHa group (p<0.0001). The
clinical pregnancy rate, implantation rate, and early pregnancy loss rate were not
significantly different between the 2 groups. So, we suggest that a single adminis-
tration of long-acting GnRHa is a useful alternative for improving patient’s conve-
nience with clinical outcomes comparable to daily administrations of short-acting
GnRHa in COH for IVF-ET cycles.
Key Words : In Vitro Fertilization-Embryo Transfer; Long-Acting GnRHa; Goserelin; Recombinant FSH; Patient’s
Convenience
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between 2 types of GnRHa were reported. Recent meta-anal-
ysis, however, reported that long-acting GnRHa required
more doses of gonadotrophin and longer duration of ovarian
stimulation (17). In this study, we aim to evaluate the clini-
cal outcome and patient’s convenience of single administra-
tion of long-acting GnRHa (goserelin depot) as compared




A total of 50 patients were included in this prospective,
case controlled study. Inclusion criteria were as follows: 1)
aged between 25 and 40 yr; 2) infertility caused by tubal
factor, endometriosis, male factor or unexplained factor; 3)
serum basal FSH concentration <10 mIU/mL and serum
basal estradiol <50 pg/mL just before starting COH; 4) pres-
ence of 2 functional ovaries and normal uterine cavity; 5) ≤3
previous IVF-ET attempts; and 6) no treatment of gonado-
trophins within 3 month before this study.
Ovarian stimulation protocol
All patients underwent pituitary desensitization by start-
ing the administration of GnRHa on day 21 of the preced-
ing IVF-ET cycle. In the long-acting GnRHa group (Group
L), patients received 3.6 mg of subcutaneous goserelin acetate
(Zoladex
� depot, AstraZeneca Ltd., Kings Langley, U.K.).
In the short-acting GnRHa group (Group S), patients were
subcutaneously administered 0.5 mg of buserelin acetate
(Superfact
�, Hoechst AG, Frankfurt, Germany) or leupro-
lide acetate (Lucrin
�, Labratories Abbot France, St. Remy
Sur Avre, France) daily at hospital before human chorionic
gonadotrophin (hCG) administration. Ovarian stimulation
was started from day 2 or 3 of the menstrual cycle with daily
self-administration (100-250 IU) of human recombinant fol-
licle-stimulating hormone (rFSH) and continued on the day
of hCG injection. The 10,000 IU of hCG (Pregnyl
�, Organon,
Oss, Netherlands) was administered when the leading folli-
cle was larger than 18 mm in mean diameter, and at least 2
follicles were larger than 16 mm. Oocytes were retrieved 36
hr after hCG injection using a 17-gauge aspiration needle
with transvaginal ultrasound guidance. 
IVF-ET
The grade of oocyte and embryo (day 2-5) was determin-
ed according to the criteria of Veeck by 3 investigators in a
blinded manner as previously described (18). Oocytes were
preincubated in the medium at 37℃ with 6% CO2 for 4-6
hr and inseminated by conventional IVF or intracytoplas-
mic sperm injection (ICSI). The fertilization was confirmed
when 2 polar bodies and 2 pronuclei were observed at 16-
20 hr after insemination. For fertilization and embryo cul-
ture, we used the sequential media system, commercially
produced by Vitrolife (GIII seriesTM, Vitrolife, Kungsbacka,
Sweden) according to the manufacturer’s guidance.
Two to four embryos were transferred into the uterine cavity
using transfer catheter (Sydney IVF
� Embryo transfer set,
Cook Ireland Ltd, Limerick, Ireland), and surplus embryos
were cryopreserved. There was no cancellation of embryo
transfer in this study. The luteal phase support was initiated
from the day before oocyte retrieval and continued up to 8
gestational weeks by progesterone in oil (Progest
�, Samil
Pharm, Seoul, Korea). The clinical pregnancy was confirmed
by the fetal heart activity using a transvaginal sonography 4
weeks after oocyte retrieval.
Statistical analysis
The statistical analysis using GraphPad InStat (GraphPad
Software, Inc., San Diego, U.S.A.) was performed with the
student’s t-test (2-tailed) or the Mann-Whitney U test (2-
tailed) for comparison of means and the chi-square test and
Fisher’s exact test for proportions. p<0.05 was considered sta-
tistically significant.
RESULTS
The group L and S had similar clinical features with respect
to age, duration of infertility, basal serum estradiol concen-
tration, and the number of previous IVF attempts (Table 1).
The serum estradiol level on hCG administration day was
significantly lower in group L (1,935.0±1,524.5 pg/mL vs.
2,630.1±1,210.0 pg/mL, p<0.05). The group L required
more gonadotrophins for COH. A total dosage of rFSH for
COH (2,354.5±244.2 IU vs. 2,012.5±626.1 IU, p<0.05)
and a mean dosage of rFSH per retrieved oocyte (336.7±
228.3 IU vs. 296.7±540.4 IU, p<0.05) were significantly
increased in group L. The duration required for ovarian stimu-
lation, the number of retrieved oocytes and produced embryos,
and the number of transferred embryos and transferred good
embryos were not significantly different in the 2 groups.
Moreover, the rate of early pregnancy loss was not different
Values are mean±SD. IVF, in vitro fertilization.
Group L Group S p value
Patients 22 28 -
Age (yr) 32.7±3.9 33.1±3.7 NS
Duration of infertility (months) 41.8±47.6 47.2±38.4 NS
Basal estradiol (pg/mL) 16.3±5.8 17.9±14.6 NS
No. of previous IVF attempts 1.5±1.4 1.6±1.2 NS
Table 1. Patients’ characteristics of the 2 groups664 K.W. Cheon, S.J. Song, B.C. Choi, et al.
between the 2 groups (5.9% vs. 6.3%, p=0.965). With res-
pect to the clinical outcomes, clinical pregnancy rate (72.7%
vs. 53.6%, p=0.275) and implantation rate (31.3% vs. 20.0%,
p=0.088) were higher in group L than those in group S, but
these differences were not statistically significant (Table 2).
Table 3 showed that there was no significant difference of
oocyte and embryo quality between the 2 groups. In addi-
tion, the fertilization rate was also similar in the 2 groups
(75.3% vs. 79.2%, p=0.343).
In Table 4, the patient’s convenience and the cost of med-
ication for COH were summarized. The frequency of visit-
ing hospital (3.3±0.5 vs. 22.2±2.0, p<0.0001) and the
total number of injections with gonadotrophin and GnRHa
(12.8±1.2 vs. 33.5±3.5, p<0.0001) were highly reduced in
group L. The total cost of gonadotrophin and GnRHa con-
sumed for COH was increased in group L (851.1±233.0
USD vs. 1,174.3±86.2 USD, p<0.0001). 
DISCUSSION
The long protocol using GnRHa and gonadotrophin has
been well known to be useful in COH of IVF-ET (11, 12).
In spite of the benefits of long protocol, multiple daily injec-
tions of GnRHa are bothersome for women undergoing COH,
including pain, psychosocial distress, and frequent hospital
visits. Moreover, Wasser et al. (19) suggested that psychoso-
cial distress contributes significantly to the etiology of some
forms of infertility. So, simplifying the process of stimula-
tion cycle is valuable to reduce patient’s inconvenience and
stress. Recently, self-injecting pen type of rFSH has been
widely used and it has been shown to improve the patient’s
convenience (20). In comparison with daily administration
of short-acting GnRHa, a single administration of long-act-
ing GnRHa can append these advantages by reducing the
number of injections in COH (13). Taken together, a single
administration of long-acting GnRHa in combination with
self-injecting pen type of rFSH can significantly improve the
patient’s convenience and comfort. In our data, the frequen-
cy of hospital visits and the number of injections (GnRHa
and gonadotrophins) were significantly decreased by using
long-acting GnRHa. In addition, the reduced number of
visiting hospital can significantly decrease the cost for med-
ical service. 
Along with previous reports (13, 14, 16, 21, 23), this study
demonstrated that a single administration of long-acting
GnRHa does not prolong the duration of ovarian stimula-
tion. However, recent meta-analytical study concluded that
the duration of ovarian stimulation was significantly increas-
ed in the long-acting GnRHa group than in short-acting
GnRHa group (17). It is noteworthy to note that the differ-
Group L Group S p value
No. of IVF-ET cycles 22 28 -
Duration of stimulation (day)* 11.8±1.2 11.3±1.6 NS
Estradiol on hCG injection 1,935.0±1524.5 2,630.1±1210.0 0.045
day*
No. of retrieved oocytes* 11.3±9.0 13.7±6.3 NS
Total dosage of rFSH for  2,354.5±244.2 2,012.5±626.1 0.034
COH (IU)*
Dosage of rFSH/oocyte  336.7±228.3 296.7±540.4 0.016
(IU/ea)*
No. of produced embryos* 5.8±2.1 6.8±2.7 NS
Transferred embryos/cycle* 3.8±0.9 3.4±1.1 NS
Transferred good embryos/ 2.6±1.7 2.4±1.2 NS
cycle*
-hCG positive cycles
� 17 (77.3) 16 (57.1) NS
Clinical pregnancy 16 (72.7) 15 (53.6) NS
Implantation rate (%) 31.3 20.0 NS
Early pregnancy loss
� 1 (5.9) 1 (6.3) NS
Table 2. Ovarian responses and clinical outcomes in the 2 groups
*Values are mean±SD; 
� -hCG ≥5 mIU/mL; 
� No fetal heart activity in
-hCG positive cycles. 
IVF-ET, in vitro fertilization and embryo transfer; hCG, human chorionic
gonadotrophin; rFSH, recombinant follicle-stimulating hormone; COH,
controlled ovarian hyperstimulation.
Values in parentheses are percentage.
Group L Group S p value
No. of retrieved oocytes 249 384 -
No. of good quality oocytes 209 (83.9) 312 (81.3) NS
(Grade I+II)
No. of poor quality oocytes 27 (10.8) 51 (13.3) NS
(Grade IV+V+VI)
No. of fertilized oocytes 162 (75.3) 259 (79.2) NS
(per inseminated oocytes)
No. of total embryos 127 189 -
No. of good quality embryos 74 (58.3) 107 (56.6) NS
(Grade I+I-1+II)
No. of poor quality embryos 53 (41.7) 82 (43.4) NS
(Grade II-1+III)
No. of transferred good embryos  57 (68.7) 66 (69.5) NS
(per total transferred embryos)
Table 3. Quality of oocytes and embryos in the 2 groups 
Values in parentheses are percentage.
Group L Group S p value
No. of hospital visits before  3.3±0.5 22.2±2.0 <0.0001
ovum pick-up
No. of injections before hCG  12.8±1.2 33.5±3.5 <0.0001
administration (rFSH+GnRHa)  
Cost of drug administration* 1,124.3±82.5 814.8±223.1<0.0001
(rFSH+GnRHa) (1,174.3±86.2)(851.1±233.0)
Table 4. Cost and convenience of controlled ovavian hyperstim-
ulation in the 2 groups 
*Values are Korean Won (×1,000).
Values in parentheses are US dollar (1 USD=957.4 Korean Won).
rFSH, recombinant follicle-stimulating hormone; GnRHa, gonadotrophin-
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ence of duration of gonadotrophin treatment was less than 1
day. So, it would be concluded that the difference of dura-
tion in ovarian stimulation was not clinically important in
both groups. 
Also, the total dose of gonadotrophin required for COH
is another important point for both physicians and the patients
to consider when choosing the type of GnRHa and protocol
because it can change the cost of COH. Numerous studies
using human menopausal gonadotrophin reported that there
was a controversy in the augmentation of total gonadotrophin
consumption in the long-acting GnRHa group as compared
with the short-acting GnRHa group (13-16, 21, 22). This
controversy was also found in other studies using highly puri-
fied urinary FSH (24, 25). In our study, the total amount of
rFSH required for COH significantly increased in the long-
acting GnRHa group as compared with the short-acting
GnRHa group, and this increased gonadotrophin consump-
tion consequently elevated the cost of COH in the long-acting
GnRHa group. From this study, however, we may suggest a
solution to compensate the increased cost of gonadotrophin
with reduced number of hospital visits. As shown in Table
4, the cost for COH was significantly increased in the long-act-
ing GnRHa group, because the total dose of rFSH increased
and the long-acting form of GnRHa was more expensive than
short-acting form. To the best of our knowledge, there has
been no report to compare the clinical efficacy of long-acting
GnRHa with that of short-acting GnRHa in combination
with self-injecting pen type rFSH. In the long protocol, the
combination of long-acting GnRHa with self-injecting pen
type rFSH can reduce the number and the cost of hospital vis-
its to have an injection of GnRHa and gonadotrophins. Con-
sequently, the total cost of COH using long-acting GnRHa
became similar to the cost using short-acting GnRHa. More-
over, the reduced frequency of injection and hospital visits can
improve the patient’s quality of life, including convenience,
less pain, and psychosocial comfort. 
No matter what benefits the use of long-acting GnRHa
may have as compared with short-acting GnRHa, the out-
come of pregnancy is the most valuable factor in IVF-ET
cycles. So, the use of long-acting GnRHa must have no detri-
mental effect on pregnancy outcome. Most of previous stud-
ies showed that there was no significant difference in preg-
nancy rate between long-acting and short-acting GnRHa
(14, 16, 21-24). In this study, the clinical pregnancy rate as
well as implantation rate was about 1.5 fold higher in the
long-acting GnRHa group than in the short-acting GnRHa
group, but this difference had no statistical significance because
of the small sample size. In addition, we found that the qual-
ity of retrieved oocytes and produced embryos was not sig-
nificantly different between the 2 groups. 
In conclusion, our study demonstrated that a single admin-
istration of long-acting GnRHa in combination with self-
injecting pen type of gonadotrophin can improve the patient’s
quality of life without a significant difference in clinical out-
comes and total cost for COH of IVF-ET cycles. So, we would
suggest that a single administration of long-acting GnRHa
as a good alternative for improving patient’s convenience and
psychosocial comfort during COH of long protocol.
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